<DOC>
	<DOCNO>NCT01816191</DOCNO>
	<brief_summary>The study single-center , open-label , safety pharmacokinetic study in12 adult subject Anal Fissures . Subjects screen determine eligibility within 7 day treatment . There three part study subject participate part .</brief_summary>
	<brief_title>An Open-Label , Single- Multi-Dose Pharmacokinetic ( PK ) Study Oral Diltiazem Topical Diltiazem Hydrochloride</brief_title>
	<detailed_description />
	<mesh_term>Fissure Ano</mesh_term>
	<mesh_term>Diltiazem</mesh_term>
	<criteria>Subjects evidence circumscribe anal fissure , induration edge . Any female nonchildbearing potential : ) hysterectomy , b ) bilateral oophorectomy , c ) bilateral tubal ligation ) postmenopausal ( demonstration total cessation menses ≥ 1 year date screen visit ) . Any female child bear potential must agree use least one form contraception ( may barrier method ) , full duration study . Able communicate adequately investigator comply requirement entire study . Capable freely willing provide write informed consent prior participate study . Unwilling visual medical examination Anal Fissure . More 1 Anal Fissure . Subjects Anal Fissure associate caused condition , include limited : druginduced , trauma , HIV infection , fistulainano , inflammatory bowel disease , perianal sepsis malignancy . Unwilling stop concomitant topical preparation apply around anus Day 1 end study . Use sitz bath signing ICF ( Informed Consent Form ) end study . Use anesthetic sign ICF end study . Subfissure injection botulinum toxin 3 month prior sign ICF . Known sensitivity investigational product ( ) calcium channel blocker . Active treatment antiviral therapy HIV ( e.g . indinavir , nelfinivir , ritonavir ) . 10 . Treatment prohibit medication within 14 day prior sign ICF : Cytochrome P450 ( CYP450 ) inhibitors inducer Cytochrome P3A4 ( CYP3A4 ) substrates , inhibitor , inducer Benzodiazepines βadrenoceptor antagonist ( BetaBlockers ) Calcium channel blocker Digoxin Investigational agent Opioids Following concomitant disease state : Sick sinus syndrome except presence function ventricular pacemaker . Secondor thirddegree Atrioventricular block except presence function ventricular pacemaker . Hypotension ( less 90 mm Hg systolic ) . Acute myocardial infarction pulmonary congestion document xray . History clinically significant renal disease . History clinically significant Alzheimer 's Parkinson 's disease . History clinically significant hepatic disease . Current infection treat macrolide antibiotic . Clinical evidence history fecal incontinence . Clinical evidence history anal fistula . Clinical evidence history anal abscess . History inflammatory bowel disease ( e.g . Crohn 's disease , Ulcerative Colitis ) . History prior anal rectal surgery include limited : lateral sphincterotomy anal stretch . History radiation therapy pelvis . Fixed anal stenosis/fibrosis . Major organ transplant . Any clinically significant laboratory abnormality screen . BMI &gt; 40 kg/m2 . Malignancy within 5 year prior randomization ( exception treat basal cell/squamous cell carcinoma skin ) . Any disease prior/planned surgery may interfere subject successfully complete study . Currently use narcotic ( ) chronically . Breastfeeding female . Employees , family member , student investigator clinical site .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>